A team from the Beth Israel Deaconess Medical Center has developed a new way to deliver anti-microRNA drugs into the tumor microenvironment. Several microRNAs, and miR-155 in particular, have been implicated in the progression of cancer, and blocking their effects via the antisense miRs (antimiRs) could be a useful therapeutic strategy.